This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Subscribe To Our Newsletter & Stay Updated
